Which funds bought or sold INSM in Q3 2026?
Insmed Inc. 6 funds bought, 6 sold, out of 109 tracked funds that have filed for Q3 2026. Among active managers, the estimated net flow was +$148M.
Holdings as of Sep 30, 2026 (Q3 2026)13F deadline Nov 16, 2026 (45 days after quarter end)
- AQR+$525M
- RBC+$127M
- Holocene+$98M
- RenaissanceNEW+$63M
- Adage+$46M
- Maverick+$42M
- D. E. Shaw−$232M
- Citadel−$210M
- Millennium−$194M
- UBS−$168M
- Balyasny−$127M
- Duquesne−$38M
Top 10 each side. NEW = opened a position, OUT = sold the whole position.
Bought (6)
Sold (6)
| Fund | Change | Est. $ | Now |
|---|---|---|---|
| D. E. Shaw Quant & multi-strategy | Trimmed-34.6% | −$232M | $439M |
| Citadel Quant & multi-strategy | Trimmed-71.8% | −$210M | $82M |
| Millennium Quant & multi-strategy | Trimmed-82.9% | −$194M | $40M |
| UBS Bank & broker | Trimmed-56.9% | −$168M | $127M |
| Balyasny Quant & multi-strategy | Trimmed-84% | −$127M | $24M |
| Duquesne Family office & foundation | Trimmed-23.3% | −$38M | $125M |
Source: SEC EDGAR Form 13F-HR for each fund, holdings as of Sep 30, 2026. Shares only (options excluded). Estimated $ = change in shares × quarter-end price. Funds may have traded since. Methodology. Not investment advice.